<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30060745</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>30</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.</ArticleTitle>            <Pagination>                <MedlinePgn>770</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4686-x</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There has been interest in the potential benefit of vitamin D (VD) to improve breast cancer outcomes. Pre-clinical studies suggest VD enhances chemotherapy-induced cell death. Vitamin D deficiency was associated with not attaining a pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for operable breast cancer. We report the impact of VD on pCR and survival in an expanded cohort.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients from Iowa and Montpellier registries who had serum VD level measured before or during NAC were included. Vitamin D deficiency was defined as &lt; 20 ng/mL. Pathological complete response was defined as no residual invasive disease in the breast and lymph nodes. Survival was defined from the date of diagnosis to the date of relapse (PFS) or date of death (OS).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 327 women. Vitamin D deficiency was associated with the odds of not attaining pCR (p = 0.04). Fifty-four patients relapsed and 52 patients died. In multivariate analysis, stage III disease, triple-negative (TN) subtype and the inability to achieve pCR were independently associated with inferior survival. Vitamin D deficiency was not significantly associated with survival in the overall sample; however a trend was seen in the TN (5-years PFS 60.4% vs. 72.3%, p = 0.3), and in the hormone receptor positive /human epidermal growth factor receptor 2 negative (HER2-) subgroups (5-years PFS 89% vs 78%, p = 0.056).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Vitamin D deficiency is associated with the inability to reach pCR in breast cancer patients undergoing NAC.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Viala</LastName>                    <ForeName>Marie</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Régional Du Cancer de Montpellier ICM, 208 Avenue des Apothicaires, Cedex-5 34298, Montpellier, France. marie.viala@icm.unicancer.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chiba</LastName>                    <ForeName>Akiko</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thezenas</LastName>                    <ForeName>Simon</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Biometry unit, Institut Régional Du Cancer de Montpellier ICM, Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Delmond</LastName>                    <ForeName>Laure</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Institut Régional Du Cancer de Montpellier ICM, Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lamy</LastName>                    <ForeName>Pierre-Jean</ForeName>                    <Initials>PJ</Initials>                    <AffiliationInfo>                        <Affiliation>Imagenome-labosud, Clinique BeauSoleil, Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mott</LastName>                    <ForeName>Sarah L</ForeName>                    <Initials>SL</Initials>                    <AffiliationInfo>                        <Affiliation>Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schroeder</LastName>                    <ForeName>Mary C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>College of Pharmacy, University of Iowa, Iowa City, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thomas</LastName>                    <ForeName>Alexandra</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine Wake Forest University School of Medicine, Winston-Salem, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jacot</LastName>                    <ForeName>William</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Régional Du Cancer de Montpellier ICM, 208 Avenue des Apothicaires, Cedex-5 34298, Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2001 Apr;7(4):1043-51</RefSource>                <PMID Version="1">11309356</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2017 Jan 1;23(1):97-103</RefSource>                <PMID Version="1">27407090</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Dec 1;32(34):3883-91</RefSource>                <PMID Version="1">25349292</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Diagn Pathol. 2009 Jun;13(3):151-7</RefSource>                <PMID Version="1">19433292</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2015 May;22(5):1441-6</RefSource>                <PMID Version="1">25727556</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Aug 10;27(23):3757-63</RefSource>                <PMID Version="1">19451439</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2018 Apr;18(2):144-149</RefSource>                <PMID Version="1">29290565</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 Jan;13(1):25-32</RefSource>                <PMID Version="1">22153890</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2011 Feb 28;6(2):e17251</RefSource>                <PMID Version="1">21386992</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Endocrinol. 1998 Jul 25;142(1-2):57-65</RefSource>                <PMID Version="1">9783903</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002</RefSource>                <PMID Version="1">17443564</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Steroids. 2012 Sep;77(11):1107-12</RefSource>                <PMID Version="1">22801352</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2014 Jul 12;384(9938):164-72</RefSource>                <PMID Version="1">24529560</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2014 Jun;3(3):693-701</RefSource>                <PMID Version="1">24719175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Mar 10;26(8):1275-81</RefSource>                <PMID Version="1">18250347</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Surg. 1995 Mar;180(3):297-306</RefSource>                <PMID Version="1">7874340</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cases J. 2009 Jul 21;2:8390</RefSource>                <PMID Version="1">19830074</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011 Jul 26;13(4):R74</RefSource>                <PMID Version="1">21791049</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Integr Cancer Ther. 2018 Jun;17(2):217-225</RefSource>                <PMID Version="1">28589744</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 May 20;30(15):1796-804</RefSource>                <PMID Version="1">22508812</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Surg Oncol. 2014 Apr 15;12:95</RefSource>                <PMID Version="1">24731479</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2001 May;47(5):429-36</RefSource>                <PMID Version="1">11391859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2016 Jul;27(7):1235-41</RefSource>                <PMID Version="1">27029707</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2016 Feb;25:69-74</RefSource>                <PMID Version="1">26614548</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2014 Mar;34(3):1163-6</RefSource>                <PMID Version="1">24596354</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2014 May-Jun;64(3):155-6</RefSource>                <PMID Version="1">24639119</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nutr. 2011 Aug;141(8):1535-42</RefSource>                <PMID Version="1">21697298</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1997 Sep 1;57(17):3759-64</RefSource>                <PMID Version="1">9288784</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 May 1;27(13):2151-6</RefSource>                <PMID Version="1">19349547</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Jul;134(2):709-17</RefSource>                <PMID Version="1">22562178</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Neo-adjuvant breast cancer</Keyword>            <Keyword MajorTopicYN="N">Vitamin D</Keyword>            <Keyword MajorTopicYN="N">pCR</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30060745</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4686-x</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4686-x</ArticleId>            <ArticleId IdType="pmc">PMC6066931</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>